Pediatric Hepatology

📚 02 Pediatric Superspecialities • 🎯 143 High-Yield MCQs • Nelson 22nd Edition Standard

Neonatal Cholestasis & Drug-Induced Hepatotoxicity

  • Drug-Induced Cholestasis: ((PHEP001)): Macrolides, specifically erythromycin, classically cause drug-induced cholestasis. Valproic acid induces hepatocellular injury and microvesicular steatosis; acetaminophen overdose causes centrilobular hepatic necrosis; isoniazid causes hepatitis-like hepatocellular necrosis.
  • Conjugated Hyperbilirubinemia Cutoff in Neonates: ((PHEP002)): Defined as direct bilirubin >1 mg/dL when total bilirubin (TB) is <5 mg/dL, or >20% of TB when total bilirubin is >5 mg/dL (AAP/NASPGHAN guidelines) to avoid false positives during high unconjugated hyperbilirubinemia.
  • Biliary Atresia Diagnostic Workup & Prognosis: ((((PHEP003)) · ((PHEP004)) · ((PHEP013)))):
  • Gold Standard Test: : Intraoperative cholangiogram.
  • HIDA Scan: : Requires 5-day phenobarbital priming (5 mg/kg/day); biliary excretion into the bowel virtually rules out extrahepatic biliary atresia (EHBA). Lack of excretion is sensitive but lacks specificity.
  • Ultrasound Findings: : Small/contracted gallbladder, non-visualization of the common bile duct, and the specific triangular cord sign (anterior wall thickening of the right portal vein). Intrahepatic duct dilatation is not a feature of EHBA.
  • Kasai Portoenterostomy: : Age at surgery is the single most critical prognostic factor (ideally performed <45–60 days of life; delays >90 days severely compromise outcomes). Liver biopsy shows bile duct proliferation, plugs, and portal stromal edema.
  • Parenteral Nutrition-Associated Cholestasis (PNAC / PNALD): ((((PHEP005)) · ((PHEP011)) · ((PHEP027)))): - Triggered by prolonged NPO status (>2 weeks) and lipid emulsions.
  • Pathophysiology: : Soybean lipid emulsions rich in pro-inflammatory ω-6 fatty acids and phytosterols impair bile flow. Conversely, fish oil emulsions containing ω-3 fatty acids are hepatoprotective.
  • Enteral Fasting: : Decreases cholecystokinin (CCK) release, causing gallbladder stasis, sludge, and stones.
  • Management: : Advance enteral feeds early to stimulate bile flow, minimize TPN duration, and consider ursodeoxycholic acid (UDCA). ---

Inherited & Metabolic Liver Diseases

  • Progressive Familial Intrahepatic Cholestasis (PFIC): ((((PHEP009)) · ((PHEP010)))):
  • Low/Normal GGT Subtypes: : PFIC1 (ATP8B1/FIC1 deficiency), PFIC2 (BSEP deficiency), and PFIC4 (TJP2) present with normal or low GGT cholestasis.
  • High GGT Subtype: : PFIC3 is characterized by elevated GGT, caused by pathogenic variants in ABCB4 (encoding the canalicular phosphatidylcholine transporter MDR3). Defective phosphatidylcholine secretion causes bile acid-induced biliary epithelial injury.
  • UDCA Response: : Efficacy in PFIC3 depends heavily on the specific ABCB4 variant (non-responders often harbor truncated proteins from premature stop codons).
  • Wilson Disease: ((((PHEP014)) · ((PHEP015)) · ((PHEP016)) · ((PHEP017)) · ((PHEP018)) · ((PHEP019)))):
  • Hemolysis: : Can present with Coombs-negative hemolytic anemia due to massive copper release from damaged hepatocytes, signifying severe, potentially fatal disease.
  • Ophthalmologic Signs: : Kayser-Fleischer rings (copper in Descemet membrane) are present in 90–100% of neurologic cases but only 40–50% of hepatic and 20–30% of presymptomatic cases; absence does not rule out the disease. Sunflower cataracts are much less common.
  • Cutaneous Sign: : Azure lunulae (“sky-blue moon” nail discoloration).
  • Histology: : Early biopsy shows mild steatosis mimicking NAFLD/NASH; later stages show interface hepatitis mimicking autoimmune hepatitis.
  • Diagnosis & Copper Studies: : Serum ceruloplasmin is typically <20 mg/dL (though acute inflammation/estrogen can falsely normalize it). 24-hour urinary copper is >0.64 µmol/24 hr. Hepatic parenchymal copper >4 µmol/g dry weight (>250 µg/g) is diagnostic.
  • Alpha-1 Antitrypsin Deficiency: ((PHEP020)): - Associated with PiZZ homozygosity. Misfolded mutant protein forms polymers retained in the endoplasmic reticulum of hepatocytes.
  • Biopsy Hallmark: : Globules that are periodic acid–Schiff (PAS)-positive and diastase-resistant in periportal hepatocytes.
  • Cystic Fibrosis Liver Disease: ((PHEP028)): - Pathognomonic lesion is focal biliary fibrosis (periductal inflammation, bile duct proliferation, and focal portal tract fibrosis), which may progress to multilobular cirrhosis and portal hypertension.
  • Nonalcoholic Fatty Liver Disease (NAFLD): ((PHEP029)): - Progression to NASH is promoted by genetic variants including PNPLA3, TM6SF2, GCKR, MBOAT7, and HSD17B13. (SERPINA1 is a mimic linked to alpha-1 antitrypsin deficiency, not a NAFLD progression gene). ---

Infections & Portal Hypertension

  • Viral Hepatitis Serology & Manifestations: ((((PHEP021)) · ((PHEP022)) · ((PHEP023)) · ((PHEP024)) · ((PHEP025)))):
  • Hepatitis B Window Period: : HBsAg clears before anti-HBs appears; IgM anti-HBc is the indispensable diagnostic marker during this interval. Most children remain in the immune-tolerant phase with a low annual rate of spontaneous HBeAg seroconversion (4–5%/year). HBV carries the highest pediatric risk of acute liver failure with cerebral edema.
  • Hepatitis C: : Only 20–40% clear the virus spontaneously; 60–80% develop persistent infection. HCV RNA (not anti-HCV antibodies) confirms active replication. Extrahepatic associations include porphyria cutanea tarda, lichen planus, and membranoproliferative glomerulonephritis. (Polyarteritis nodosa is classically linked to HBV, not HCV).
  • Primary Sclerosing Cholangitis (PSC): ((PHEP026)): - Strongly associated with ulcerative colitis in children. Cholangiography is diagnostic, classically demonstrating multifocal strictures and dilatations with a “beaded” appearance.
  • Caroli Syndrome vs. Disease: ((PHEP031)): - Caroli disease is isolated nonobstructing segmental dilatation of large intrahepatic ducts. Caroli syndrome is more common and distinguished by its association with congenital hepatic fibrosis, predisposing patients to recurrent ascending cholangitis.
  • Gallbladder Hydrops: ((PHEP032)): - Acute noncalculous, noninflammatory distension seen in Kawasaki disease, typhoid fever, sepsis, and TPN. Cystic fibrosis is not a typical cause of acute gallbladder hydrops.
  • Portal Hypertension & Vascular Etiologies: ((PHEP033)):
  • Extrahepatic Portal Hypertension: : Caused by portal vein agenesis/atresia, splenic vein thrombosis, or arteriovenous fistulas. Budd-Chiari syndrome is a postsinusoidal/posthepatic cause, not extrahepatic portal hypertension. ---

Pancreatic Disorders, Acute Liver Failure & Transplantation

  • Acute Pancreatitis Enzymes: ((PHEP008)):
  • Serum lipase: is superior to amylase; it rises within 4–8 hours, peaks at 24–48 hours, and remains elevated longer (8–14 days vs. up to 4 days for amylase). Normal early amylase does not exclude pancreatitis.
  • Pancreatic Enzyme Replacement Therapy (PERT): ((PHEP007)): - Corrects protein malabsorption and improves growth, but fat malabsorption (steatorrhea) often persists due to inadequate active lipase delivery, incorrect timing, or gastric acid inactivation of enzymes.
  • Acute Liver Failure (ALF): ((PHEP030)): - A rapidly decreasing liver span without clinical improvement is an ominous sign indicating extensive hepatocellular necrosis and loss of functioning liver mass.
  • Liver Transplantation Indications & Graft Options: ((((PHEP034)) · ((PHEP035)))): - Indicated for metabolic defects without primary liver parenchymal damage, such as urea cycle defects.
  • Graft Innovations: : Split-liver transplantation allows the left lateral segment to be grafted into a pediatric recipient while larger segments go to an adult. Reduced-size grafts are typically prepared ex vivo.

Neonatal Cholestasis & Biliary Atresia

  • Biliary Atresia: ((((PHEP036)) · ((PHEP040)) · ((PHEP058)))): Progressive obliterative cholangiopathy of the extrahepatic biliary system presenting with persistent jaundice, pale (acholic) stools, dark urine, and hepatomegaly in a well-appearing infant. Ultrasound shows a small or absent gallbladder with non-visualization of the common bile duct. Type III is the most severe and common variant with obstruction extending to the porta hepatis. Intraoperative cholangiogram (IOC) is the gold standard for confirmation and immediate Kasai portoenterostomy (ideally performed <60 days of life). May be part of BASM syndrome (Biliary Atresia Splenic Malformation: polysplenia, situs inversus, cardiac anomalies).
  • Alagille Syndrome: ((PHEP060)): Multisystem disorder with chronic cholestasis that worsens until 5–6 years of age, often stabilizing thereafter. Features prominent, debilitating pruritus appearing within the first 6 months. Treated with traditional choleretics and ileal bile acid transporter (IBAT) inhibitors (maralixibat, odevixibat) to lower serum bile acids. Mortality is largely driven by cardiac and vascular complications (e.g., pulmonary stenosis) rather than liver failure alone.

Progressive Familial Intrahepatic Cholestasis (PFIC) & Benign Recurrent Intrahepatic Cholestasis (BRIC)

  • PFIC Type 2 (ABCB11 Deficiency): ((PHEP061)): Canalicular bile salt export pump (BSEP) deficiency causing low/normal gamma-glutamyl transferase (GGT) cholestasis, severe pruritus, and neonatal hepatitis with giant cell transformation. High risk for early hepatocellular carcinoma (HCC) and potential disease recurrence post-liver transplant due to anti-BSEP antibodies.
  • PFIC Type 1 & BRIC 1 (ATP8B1/FIC1 Deficiency): ((PHEP062)): Caused by aminophospholipid transporter defects. BRIC1 presents with episodic, self-limited attacks of jaundice and severe pruritus with complete interictal normalization of liver function and normal/low GGT, contrasting with the progressive persistent cholestasis seen in PFIC1.
  • Progressive Familial Intrahepatic Cholestasis (PFIC) Management: ((PHEP039)): For cases with severe intractable pruritus unresponsive to medical therapy (ursodeoxycholic acid, antihistamines) and preserved hepatic function, partial external biliary diversion (PEBD) provides significant symptomatic relief.

Neonatal & Pediatric Hyperbilirubinemia Syndromes

  • Crigler-Najjar Syndrome Type I vs. Type II: ((((PHEP044)) · ((PHEP066)))): Severe unconjugated hyperbilirubinemia without hemolysis. Type I involves complete absence of UGT1A1 activity, non-responsive to phenobarbital, requiring phototherapy/transplant. Type II features reduced UGT1A1 activity (<10%) with unconjugated bilirubin dropping significantly (by 70-80% to 2-3 mg/dL) within 7-10 days of phenobarbital therapy.
  • Gilbert Syndrome: ((PHEP067)): Most common inherited hyperbilirubinemia. Caused by UGT1A1 promoter polymorphism (TA insertion in the TATA box). Presents post-puberty with mild, fluctuating unconjugated hyperbilirubinemia (1–6 mg/dL) precipitated by fasting, dehydration, or stress, with entirely normal liver enzymes and no hemolysis.
  • Dubin-Johnson Syndrome: ((((PHEP068)) · ((PHEP069)))): Autosomal recessive defect of canalicular organic anion transporter MRP2 (ABCC2) causing benign, fluctuating conjugated hyperbilirubinemia with normal liver function and normal serum bile acids. Urine coproporphyrin excretion is normal in amount, but coproporphyrin I is elevated to ~80% (normal: isomer III >75%). Liver biopsy characteristically shows normal architecture with dark melanin-like pigment in hepatocytes.
  • Breast Milk Jaundice: ((PHEP043)): Occurs in thriving, exclusively breastfed infants at 3–6 weeks of age due to substances inhibiting bilirubin conjugation (e.g., pregnane-3α,20β-diol). Confirmed via a brief 24–48 hour interruption of breastfeeding, after which breastfeeding is safely resumed.

Hemolytic Anemias Presenting in Neonates/Children

  • Hereditary Spherocytosis: ((PHEP041)): Manifests with unconjugated hyperbilirubinemia and hemolysis (low Hb, high retics, negative direct Coombs). MCHC/MCV ratio >0.36 is a strong screening indicator. Confirmed via incubated osmotic fragility test or EMA-binding test.
  • G6PD Deficiency: ((PHEP042)): Non-immune hemolytic anemia triggered by oxidative stress (infections, drugs). Peripheral smear features bite cells (from splenic removal of Heinz bodies). Caution: Quantitative G6PD enzyme assays during acute hemolysis can yield false negatives because older deficient cells are lysed and reticulocytes have high enzyme activity; retest later if clinical suspicion remains high.

Portal Hypertension & Vascular Complications

  • Portopulmonary Hypertension: ((PHEP057)): Pulmonary arterial hypertension occurring secondary to portal hypertension. Presents with exertional dyspnea, fatigue, palpitations, and syncope with echocardiographic evidence of right-sided heart pressure overload, differing from hepatopulmonary syndrome (which features hypoxemia, platypnea, and orthodeoxia from intrapulmonary vascular dilations).

Pediatric Pancreatic Disorders

  • Annular Pancreas: ((PHEP049)): Congenital anomaly resulting from incomplete ventral anlage rotation causing duodenal obstruction. Treatment of choice is duodenojejunostomy to bypass the obstruction. Do not divide the pancreatic ring due to high risks of pancreatic fistula/duodenal injury and frequent co-existing intrinsic duodenal atresia/stenosis.
  • Pancreas Divisum: ((PHEP050)): Most common pancreatic ductal anomaly (failure of dorsal and ventral duct fusion). Can cause recurrent acute pancreatitis due to restricted drainage through the accessory duct of Santorini. Strongly associated with pathogenic CFTR variants.
  • Genetic & Autoimmune Pancreatitis: ((((PHEP053)) · ((PHEP054)))):
  • SPINK1: : Encodes a pancreatic trypsin inhibitor; pathogenic variants cause loss of the fail-safe autoactivation guard, predisposing to acute recurrent and chronic pancreatitis.
  • Autoimmune Pancreatitis Type 2: : Pediatric-predominant form presenting with diffuse pancreatic enlargement/hypodensity, normal IgG4 levels, and lack of systemic IgG4 extrapancreatic findings (unlike Type 1). Responds well to corticosteroids.
  • Pancreatic Pseudocyst: ((PHEP055)): Encapsulated, well-defined fluid collection rich in pancreatic enzymes with minimal solid debris, developing >4 weeks after an episode of acute pancreatitis.
  • Solid Pseudopapillary Tumor (Frantz Tumor): ((PHEP056)): Indolent, well-circumscribed pancreatic neoplasm occurring predominantly in adolescent females. Curative via complete surgical excision, carrying an excellent long-term prognosis.

Liver Infections & Miscellaneous Hepatology

  • Hepatitis A Virus (HAV): ((PHEP037)): Picornavirus transmitted via fecal-oral route. Causes acute, benign self-limited hepatitis with never progressing to chronicity. Children are frequently anicteric or asymptomatic. Confirmed by anti-HAV IgM.
  • Amoebic Liver Abscess (ALA): ((PHEP048)): Favors older children and adolescent males in tropical regions. Presents with high fever, tender hepatomegaly, and right-sided intercostal tenderness due to diaphragmatic irritation. Ultrasound shows a solitary, uniloculated, liquefied hypoechoic lesion in the right liver lobe with sterile blood cultures.
  • Gestational Alloimmune Liver Disease (GALD): ((PHEP064)): Leading cause of neonatal liver failure in the first week of life. Characterized by severe coagulopathy, hypoglycemia, conjugated hyperbilirubinemia, and markedly elevated serum ferritin with disproportionately mild transaminase elevations and a history of prior unexplained fetal loss.
  • Nutritional Support in Cholestasis: ((PHEP065)): Requires energy intake at ~130% of baseline with fats providing 30–50% of total calories. The optimal fat composition utilizes a medium-chain to long-chain triglyceride (MCT:LCT) ratio of 30:70.
  • Wilson Disease Screening: ((PHEP070)): First-degree relatives of a proband require screening via serum ceruloplasmin and 24-hour urinary copper excretion. If results are equivocal, proceed directly to liver biopsy to quantify hepatic copper content and assess architectural morphology before clinical symptoms appear.

Wilson Disease & Indian Childhood Cirrhosis

  • Wilson Disease Dietary Management: ((PHEP071)): Lifelong treatment requires restricting dietary copper to <1 mg/day (normal diet contains 2-5 mg/day). Must avoid high-copper foods: liver, shellfish, nuts, and chocolate. Drinking water should be checked if copper exceeds 0.1 mg/L.
  • Neurologic Wilson Disease Management: ((PHEP072)): Penicillamine may initially worsen neurological symptoms. Ammonium tetrathiomolybdate causes fewer neurologic deteriorations than penicillamine, though adverse effects include cytopenias, mild transaminitis, and antiangiogenic activity.
  • Investigational Adjuncts in Wilson Disease: ((PHEP073)): Curcumin acts as both an antioxidant and a pharmacologic chaperone. Vitamin E functions solely as an antioxidant adjunct.
  • Indian Childhood Cirrhosis: ((PHEP074)): Characterized by jaundice, pruritus, lethargy, hepatosplenomegaly, and rapid progression to cirrhosis with high early mortality (40-50% within 4 weeks). Liver histology reveals hepatocyte necrosis, Mallory bodies, intralobular fibrosis, inflammation, and excess copper (a late-stage association). Treatment is mainly supportive in advanced disease.

Viral Hepatitis & Serology

  • Prolonged Cholestatic Hepatitis A: ((PHEP075)): Can present with waxing and waning jaundice, pruritus, and fat malabsorption over several months, but crucially features normal liver synthetic function (normal PT/INR and albumin) and resolves without sequelae.
  • Chronic Hepatitis B Serology: ((((PHEP076)) · ((FHEP078)))): - Chronic HBV: HBsAg positive, anti-HBc IgG positive, anti-HBc IgM negative, anti-HBs negative. - Isolated anti-HBc: HBsAg negative, total anti-HBc positive, IgM anti-HBc negative, anti-HBs negative (can indicate false-positive, remote past infection, or low-level chronic infection).
  • Diagnosis of Acute Hepatitis A: ((PHEP077)): Diagnosed by detecting anti-HAV IgM positive alongside raised ALT/AST; anti-HAV IgM remains positive for 4–6 months.
  • Causes of Hepatitis Flares in HBV: ((PHEP079)): Flares during the second to third month of interferon therapy are common (~30% of patients) and often herald a virologic response.
  • Age-Dependent HBV Progression: ((PHEP080)): Risk of viral persistence is inversely proportional to age at infection: neonates have lowest recovery (~5%) and highest chronicity risk, children aged 1–5 years have ~70% recovery, and children >5 years have ~95% recovery.
  • Extrahepatic Manifestations of HBV: ((PHEP081)): Associated with polyarteritis nodosa, glomerulonephritis, papular acrodermatitis (Gianotti-Crosti syndrome), and serum sickness-like prodrome. Henoch-Schönlein purpura is NOT associated with HBV.
  • Antiviral Resistance in HBV: ((PHEP082)): Prior lamivudine resistance significantly increases the risk of subsequent resistance to entecavir.
  • Immune-Tolerant Phase of Chronic HBV: ((PHEP083)): Characterized by HBeAg-positivity, high HBV DNA, and normal ALT/AST. Treatment should be deferred as current therapies are ineffective in this phase.
  • HBsAg-Positive Mother Prophylaxis (<2000g infant): ((PHEP084)): Requires both Hepatitis B vaccine AND HBIG within 12 hours of birth at different anatomical sites, followed by a 4-dose schedule (birth, 1 month, 2-3 months, and 6 months).

Hepatitis C & Direct-Acting Antivirals (DAAs)

  • Pediatric HCV Treatment (Genotype 1): ((PHEP085)): The first pediatric trial established safety and efficacy of ledipasvir with sofosbuvir for 12 weeks in children aged 12-17 years (now approved down to age 3).
  • Pangenotypic HCV Regimens: ((PHEP086)): Sofosbuvir-velpatasvir is dosed daily for 12 weeks, while glecaprevir-pibrentasvir is given for 8 weeks.
  • HCV Therapy Monitoring: ((PHEP087)): Treatment response is monitored via HCV PCR at baseline, 12 weeks, and 24 weeks after starting DAA therapy.

Specialized Liver Disorders & Complications

  • Acute Liver Failure Initial Triage: ((PHEP088)): Prolonged PT/INR, hypoglycemia, and encephalopathy mandate immediate referral to a liver transplantation center, regardless of transaminase trends.
  • Intestinal Failure–Associated Liver Disease (IFALD): ((PHEP089)): Management includes trophic feeds, lipid reduction, fish-oil containing lipid emulsions, and oral ursodeoxycholic acid. Cycling TPN with reduced enteral stimulation is NOT an evidence-based strategy (enteral stimulation should be maximized).
  • Sinusoidal Obstruction Syndrome (VOD): ((PHEP090)): Occurs within 21 days post-HSCT, presenting with jaundice, painful hepatomegaly, ascites, and rapid weight gain. Defibrotide is the treatment of choice.
  • NASH Pharmacotherapy Contraindications: ((PHEP091)): SGLT2 inhibitors improve hepatic steatosis but are contraindicated if eGFR is <45 mL/min/1.73 m² (e.g., eGFR of 38 mL/min/1.73 m²).
  • Autoimmune Hepatitis (AIH) Subtypes: ((((PHEP092)) · ((PHEP093)) · ((PHEP094)) · ((PHEP095)))): - AIH Type 1: Characterized by ANA and/or anti-smooth muscle antibody (SMA) positivity. - AIH Type 2: Associated with anti-LKM-1 positivity. - Budesonide: Can replace prednisone only if there is no cirrhosis and no severe acute AIH. - Overlap Syndrome: Persistent cholestatic enzymes with sclerosing cholangitis changes on MRCP require a liver biopsy for confirmation. - Response Timeline: While transaminases and bilirubin normalize within 1-3 months, albumin and prothrombin time take 3-9 months to improve.

Drug-Induced Liver Injury (DILI) & Acute Liver Failure (ALF)

  • Antibiotic-Induced Cholestatic DILI: ((PHEP096)): Amoxicillin-clavulanate classically causes cholestatic injury that is frequently detected after drug cessation.
  • Valproate Hepatotoxicity: ((((PHEP097)) · ((PHEP098)))): Can cause a Reye-like syndrome characterized by microvesicular steatosis on liver biopsy. Antidotal/supportive management includes intravenous L-carnitine (contrasting with N-acetylcysteine for acetaminophen).
  • Hepatic Encephalopathy Staging: ((PHEP099)): Stage II encephalopathy features drowsiness, inappropriate behavior, decreased inhibitions, hyperreflexia, and generalized slowing with triphasic waves on EEG.
  • Precipitating Factors in ALF Encephalopathy: ((PHEP100)): Gastrointestinal hemorrhage (increases nitrogen load) and sedatives precipitate or worsen hepatic encephalopathy and must be avoided/corrected.
  • Coagulopathy Management in ALF: ((PHEP101)): Coagulopathy (prolonged INR) reflects synthetic failure and should not be corrected routinely; avoid correction unless there is active bleeding or invasive procedures.
  • King’s College Criteria for Prognosis in ALF: ((((PHEP102)) · ((PHEP103)))): - Acetaminophen-induced: Arterial pH <7.30 (after resuscitation), or PT >100 seconds + creatinine >3.4 mg/dL + grade III/IV encephalopathy. - Non-acetaminophen: Serum bilirubin >17.4 mg/dL is a poor prognostic criterion (unlike acetaminophen-specific criteria).

Portal Hypertension & Biliary Malformations

  • Congenital Hepatic Fibrosis: ((PHEP104)): Classically linked with autosomal recessive polycystic kidney disease (ARPKD), presenting with massive splenomegaly and variceal bleeding while hepatocellular function remains well preserved (normal bilirubin, albumin, and PT).
  • Choledochal Malformations: ((PHEP105)): Type I (fusiform dilatation of the common bile duct) carries risks of cholangitis, biliary cirrhosis, and cholangiocarcinoma; definitive treatment is surgical excision with Roux-en-Y choledochojejunostomy.

Gallbladder & Biliary Tract Pathology in Children

  • Brown Pigment Gallstones: ((PHEP106)): Associated with infants having obstructive jaundice and infected intrahepatic/extrahepatic bile ducts; stones are radiolucent and form via high $\beta$-glucuronidase activity in infected bile leading to unconjugated bilirubin. - Distractors & Pearls: Cholesterol stones are increasingly seen in obese children but lack the classic infection link. Black pigment stones are classically tied to chronic hemolytic states (e.g., sickle cell disease, thalassemia).
  • Choledocholithiasis Presentation: ((PHEP107)): Recurrent right upper quadrant colicky pain with markedly elevated direct bilirubin, alkaline phosphatase, and GGT points directly to common bile duct obstruction. - Distractors & Pearls: While acute calculous cholecystitis presents with fever, RUQ pain, and a palpable gallbladder (sometimes mild hyperbilirubinemia), prominent cholestatic enzymes mandate evaluation for choledocholithiasis.
  • Management of Asymptomatic Cholelithiasis in Sickle Cell Disease: ((PHEP108)): Elective laparoscopic cholecystectomy is indicated upon diagnosis even if asymptomatic to prevent catastrophic acute cholecystitis, choledocholithiasis, or pancreatitis. - Distractors & Pearls: Pure observation may be reserved for selected asymptomatic non-hemolytic patients where spontaneous resolution is possible, but never delay intervention in chronic hemolysis.

Vascular & Circulatory Liver Complications

  • Sinusoidal Obstclusion Syndrome: ((PHEP109)): Formerly veno-occlusive disease; most common cause of hepatic vein obstruction in children, classically triggered by total body irradiation with or without cytotoxic drug therapy in bone marrow transplant recipients.
  • Portal Hypertension Clinical Presentation: ((((PHEP110)) · ((PHEP111)) · ((PHEP112)) · ((PHEP134)))): - Presentation: Hematemesis or melena (due to esophageal variceal rupture) is the most common presenting sign (~two thirds of children); splenomegaly is the second most common. - Acute Variceal Bleeding: Octreotide is the preferred first-line pharmacotherapy due to superior reduction of splanchnic blood flow compared to systemic vasoconstrictors like vasopressin (which impairs organ perfusion). - Surgical Shunting: The Meso-Rex shunt (connecting superior mesenteric vein to left portal vein) restores physiologic portal venous inflow and hepatotrophic factors in extrahepatic portal vein thrombosis with preserved liver function. - Definitions: Normal portal pressure is 1–5 mm Hg; portal hypertension is defined at $\ge$ 6 mm Hg, while clinically significant portal hypertension exceeds 10–12 mm Hg (the threshold for ascites and variceal bleeds).

Pediatric Liver Transplantation Complications

  • Maintenance Immunosuppression: ((PHEP113)): Tacrolimus is the primary calcineurin phosphatase inhibitor, blocking interleukin-2 production to prevent T-cell acute cellular rejection while uniquely enabling steroid-free maintenance.
  • Early Vascular Complications: ((PHEP114)): Hepatic artery thrombosis (5–10% of recipients) is the most frequent early vascular catastrophe, risking graft necrosis, bilomas, and urgent retransplantation.

Metabolic, Genetic, and Structural Liver & Pancreatic Disorders

  • Shwachman-Diamond Syndrome: ((PHEP115)): Caused by pathogenic variants in the SBDS gene; characterized by exocrine pancreatic insufficiency (fatty replacement with preserved size/contour on CT), failure to thrive, recurrent infections (neutropenia), and metaphyseal dysostosis.
  • Alagille Syndrome: ((PHEP116)): Multisystem disorder defined by intrahepatic bile duct paucity, posterior embryotoxon, butterfly vertebrae, and characteristic facies. The most characteristic cardiovascular anomaly is peripheral pulmonary artery stenosis.
  • Wilson Disease: ((PHEP117)): Exhibiting Kayser-Fleischer rings, tremors, dystonia, dysarthria, and psychiatric disturbances. - Distractors & Pearls: Progressive cognitive decline, peripheral neuropathy, and pigmentary retinopathy are not classic features of Wilson disease.
  • Non-Alcoholic Fatty Liver Disease (NAFLD) vs. LAL Deficiency: ((PHEP118)): NAFLD typically demonstrates macrovesicular steatosis alone (large fat vacuoles). - Distractors & Pearls: Lysosomal acid lipase deficiency (LIPA gene mutation) characteristically features microvesicular or mixed microvesicular/macrovesicular steatosis alongside foamy macrophage aggregates.

Clinical Examination Signs & Diagnostics in Pediatric Hepatology

  • Jaundice Thresholds: ((PHEP119)): Visually apparent jaundice requires serum bilirubin levels of 2–3 mg/dL in older children and adults, but exceeds 5 mg/dL in neonates.
  • Caput Medusae Blood Flow: ((PHEP120)): In portal hypertension, paraumbilical veins recanalize, showing centrifugal flow away from the umbilicus (superiorly above, inferiorly below).
  • Ascites Examination Techniques: ((((PHEP121)) · ((PHEP122)) · ((PHEP123)))): - Shifting Dullness: Percuss umbilicus to flank $\rightarrow$ mark dullness $\rightarrow$ turn patient to opposite side $\rightarrow$ wait 10 seconds for fluid redistribution $\rightarrow$ percuss again. - Fluid Thrill: A tap on one flank transmits an impulse; to eliminate false positives from abdominal wall fat transmission, place the ulnar edge of a hand firmly along the midline.
  • Splenic Palpation Modification: ((PHEP124)): If unpalpable, place the left hand behind the patient's left lower ribs and pull the rib cage forward while elevating the spleen to bring it into the path of the right examining hand.
  • Auscultation & Anatomy: ((((PHEP125)) · ((PHEP126)) · ((PHEP127)))): - Hepatic Bruit: The most common explanation for an audible bruit over the liver is the transmission of a cardiac murmur. - Liver Span Assessment: A low palpable edge does not confirm hepatomegaly; percussion of the upper border of dullness in the midclavicular line is mandatory to calculate the true liver span (normal at 12 years: 7–8 cm in males, 6–6.5 cm in females). - Intra-abdominal Swellings: Omental cysts demonstrate minimal/no respiratory movement while remaining freely mobile on palpation.
  • Complications of Chronic Liver Disease & Cholestasis: ((((PHEP129)) · ((PHEP130)) · ((PHEP131)) · ((PHEP132)) · ((PHEP133)) · ((PHEP135)) · ((PHEP136)) · ((PHEP137)) · ((PHEP138)) · ((PHEP139)) · ((PHEP140)))): - Cholestatic Pruritus: Characteristically worse at night and with heat, relieved by cool temperatures; severity is unrelated to the degree of hyperbilirubinemia. Sertraline acts via serotonin reuptake inhibition (not as an ileal bile acid transporter inhibitor). - Estrogen-Related Stigmata: Spider angiomas (central pulsating arteriole with fine radiating vessels, blanching centrally, predominant over face/chest) and palmar erythema (most prominent over the thenar eminence, hypothenar eminence, and finger tips) are driven by altered estrogen metabolism. - Ascites Starling Forces: Promoted by decreased plasma colloid osmotic pressure (hypoalbuminemia) and increased capillary hydrostatic pressure. - Hepatorenal Syndrome: Functional renal failure with urine $Na$ <10 mEq/L, $FeNa$ <1%, urine:plasma creatinine ratio <10, and normal urinary sediment. - Hepatopulmonary Syndrome: Suspect in chronic liver disease with resting or orthodeoxic desaturation (oxygen saturation <96% particularly in the upright position) due to intrapulmonary vascular dilations. - Cholestasis Enzymes: Sensitive biliary obstruction panel includes alkaline phosphatase, $5'$-nucleotidase, and $\gamma$-glutamyl transpeptidase (GGT). - Biliary Imaging: In infants with dilated intrahepatic ducts, direct cholangiography via percutaneous transhepatic cholangiography (PTC) is the investigation of choice.

Pediatric Hepatology & Micronutrient Deficiencies

  • Intrahepatic vs. Extrahepatic Neonatal Cholestasis: ((PHEP141)): Neonatal cholestasis stems from either intrahepatic or extrahepatic pathology. Intrahepatic causes feature bile duct paucity, decreased canalicular flow, and dysfunctional plasma membrane transporters. Choledochal malformations and biliary atresia primarily involve the extrahepatic biliary system and are excluded when primary intrahepatic duct abnormalities are identified.
  • Vitamin E Deficiency in Chronic Liver Disease: ((PHEP142)): Fat-soluble vitamin malabsorption in chronic liver disease leads to Vitamin E deficiency, presenting with a triad of posterior column dysfunction (loss of position/vibration sense, ataxia), generalized muscle wasting, and ocular findings (retinitis pigmentosa-like changes, night blindness). Vitamin A deficiency causes isolated night blindness and xerophthalmia without posterior column ataxia. Vitamin B1 (thiamine) deficiency manifests as beriberi or Wernicke encephalopathy, while Vitamin B12 deficiency causes combined spinal cord degeneration with megaloblastic anemia.
  • Bilirubin Handling Profiles in Jaundice: ((PHEP143)): Hepatocellular jaundice is characterized by dark urine, urine bilirubin ++, urine urobilinogen ++, and normal stool color because conjugated bilirubin leaks into the blood/urine while partial biliary excretion continues into the gut. In contrast, complete extrahepatic biliary obstruction (e.g., biliary atresia) results in pale/acholic stools, urine bilirubin ++++, and absent urobilinogen.